These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 17823306)

  • 1. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
    Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
    J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory.
    Wall PM; Messier C
    Psychopharmacology (Berl); 2002 Mar; 160(3):233-44. PubMed ID: 11889492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein synthesis and the mechanisms of lasting change in anxiety induced by severe stress.
    Adamec R; Strasser K; Blundell J; Burton P; McKay DW
    Behav Brain Res; 2006 Feb; 167(2):270-86. PubMed ID: 16256211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat.
    Steiner MA; Lecourt H; Rakotoariniaina A; Jenck F
    Behav Brain Res; 2011 Aug; 221(1):34-42. PubMed ID: 21354212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.
    Zarrindast MR; Sarahroodi S; Arzi A; Khodayar MJ; Taheri-Shalmani S; Rezayof A
    Behav Pharmacol; 2008 Oct; 19(7):716-23. PubMed ID: 18797248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
    Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
    Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
    Mague SD; Pliakas AM; Todtenkopf MS; Tomasiewicz HC; Zhang Y; Stevens WC; Jones RM; Portoghese PS; Carlezon WA
    J Pharmacol Exp Ther; 2003 Apr; 305(1):323-30. PubMed ID: 12649385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
    Pietraszek M; Sukhanov I; Maciejak P; Szyndler J; Gravius A; Wisłowska A; Płaźnik A; Bespalov AY; Danysz W
    Eur J Pharmacol; 2005 May; 514(1):25-34. PubMed ID: 15878321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiogenic treatments do not increase fear-potentiated startle in mice.
    Risbrough VB; Geyer MA
    Biol Psychiatry; 2005 Jan; 57(1):33-43. PubMed ID: 15607298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study with two types of elevated plus-maze (transparent vs. opaque walls) on the anxiolytic effects of midazolam, one-trial tolerance and fear-induced analgesia.
    Albrechet-Souza L; Oliveira AR; De Luca MC; Tomazini FM; Santos NR; Brandão ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):571-9. PubMed ID: 15866360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.
    Peters MF; Zacco A; Gordon J; Maciag CM; Litwin LC; Thompson C; Schroeder P; Sygowski LA; Piser TM; Brugel TA
    Eur J Pharmacol; 2011 Jul; 661(1-3):27-34. PubMed ID: 21539838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.
    Knoll AT; Muschamp JW; Daws SE; Ferguson D; Dietz DM; Meloni EG; Carroll FI; Nestler EJ; Konradi C; Carlezon WA
    Biol Psychiatry; 2011 Sep; 70(5):425-33. PubMed ID: 21531393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporary inactivation of the rostral perirhinal cortex induces an anxiolytic-like effect on the elevated plus-maze and on the yohimbine-enhanced startle response.
    Schulz-Klaus B; Fendt M; Schnitzler HU
    Behav Brain Res; 2005 Sep; 163(2):168-73. PubMed ID: 16029901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.
    Engin E; Treit D; Dickson CT
    Neuroscience; 2009 Jun; 161(2):359-69. PubMed ID: 19321151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dorsal periaqueductal gray modulates the increased fear-like behavior exhibited by experienced rats in the elevated plus-maze.
    Kincheski GC; Carobrez AP
    Behav Brain Res; 2010 Jan; 206(1):120-6. PubMed ID: 19737580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
    Beardsley PM; Howard JL; Shelton KL; Carroll FI
    Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.